Specify a stock or a cryptocurrency in the search bar to get a summary
Novavax Inc
NVV1Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. Address: 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878
Analytics
WallStreet Target Price
19.6 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures NVV1
Dividend Analytics NVV1
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History NVV1
Stock Valuation NVV1
Financials NVV1
Results | 2019 | Dynamics |